Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Cel-Sci Corp (CVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,752
  • Shares Outstanding, K 33,703
  • Annual Sales, $ 480 K
  • Annual Income, $ -31,840 K
  • 60-Month Beta 1.78
  • Price/Sales 324.31
  • Price/Cash Flow N/A
  • Price/Book 158.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +72.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 +5.10%
on 05/23/19
8.47 -44.04%
on 05/09/19
-1.96 (-29.25%)
since 04/24/19
3-Month
2.37 +100.00%
on 03/01/19
8.47 -44.04%
on 05/09/19
+1.86 (+64.58%)
since 02/22/19
52-Week
0.82 +478.05%
on 08/10/18
8.47 -44.04%
on 05/09/19
+1.74 (+58.26%)
since 05/24/18

Most Recent Stories

More News
CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2019. The Company also reported key clinical and corporate developments achieved...

CVM : 4.74 (+3.27%)
CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting

--This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine.

CVM : 4.74 (+3.27%)
CEL-SCI Corporation Releases Letter to Shareholders

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders:

CVM : 4.74 (+3.27%)
CEL-SCI to Present at the ThinkEquity Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the ThinkEquity Conference...

CVM : 4.74 (+3.27%)
Healthcare Companies Search for New Ways to Oppose the Spread of Cancer

Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...

CRIS : 1.48 (-3.90%)
CVM : 4.74 (+3.27%)
GERN : 1.55 (+1.97%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0102 (-19.69%)
NLNK : 1.89 (+4.42%)
Biotech Brief: Growing Number of Ongoing Clinical Trials for Leukemia (AML) Brings New Hope

In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: "… There are over 400 phase 2 or...

CHRS : 20.36 (unch)
CVM : 4.74 (+3.27%)
INO : 3.26 (+0.31%)
INSM : 26.33 (+1.98%)
MBRX : 1.11 (-0.89%)
Detailed Research: Economic Perspectives on Cel-Sci, Vermilion Energy, Matrix Service, Turtle Beach, Consolidated Water Co., and Synlogic -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cel-Sci Corporation (NYSE:CVM),...

VET : 21.73 (+1.54%)
MTRX : 18.93 (+0.85%)
CVM : 4.74 (+3.27%)
SYBX : 8.20 (unch)
HEAR : 8.55 (-1.16%)
CWCO : 13.75 (+0.22%)
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational...

CVM : 4.74 (+3.27%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation

Levi & Korsinsky announces it has commenced an investigation of CEL-SCI Corporation (NYSEAMERICAN: CVM) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

CVM : 4.74 (+3.27%)
Therapies Trying to Fight Against Cancer

Over the past two decades, U.S. cancer-related deaths have significantly declined. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American Cancer...

AGEN : 2.86 (-3.38%)
APTO : 2.03 (+2.53%)
INO : 3.26 (+0.31%)
GILD : 66.89 (-0.42%)
CVM : 4.74 (+3.27%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0102 (-19.69%)
APS.TO : 2.71 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CVM with:

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

2nd Resistance Point 5.27
1st Resistance Point 5.00
Last Price 4.74
1st Support Level 4.52
2nd Support Level 4.31

See More

52-Week High 8.47
Fibonacci 61.8% 5.55
Last Price 4.74
Fibonacci 50% 4.64
Fibonacci 38.2% 3.74
52-Week Low 0.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar